Article
Microbiology
Vidmantas Petraitis, Ruta Petraitiene, Povilas Kavaliauskas, Ethan Naing, Andrew Garcia, Naoki Ishibashi, Benjamin Georgiades, Roger Echols, Robert A. Bonomo, Yoshinori Yamano, Michael J. Satlin, Thomas J. Walsha
Summary: Cefiderocol demonstrates high efficacy in the treatment of S. maltophilia pneumonia, leading to improved survival rate, reduced bacterial burden, and lung injury in a rabbit model.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Microbiology
Rio Nakamura, Merime Oota, Shuhei Matsumoto, Takafumi Sato, Yoshinori Yamano
Summary: Cefiderocol is a novel antibiotic that shows potent activity against difficult-to-treat Gram-negative bacteria, including strains resistant to carbapenems. In in vitro and animal studies, Cefiderocol demonstrated strong antimicrobial activity against Stenotrophomonas maltophilia, even against strains resistant to trimethoprim-sulfamethoxazole. These results suggest that Cefiderocol could be a promising treatment option for infections caused by S. maltophilia, especially those resistant to traditional antibiotics.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Immunology
Alice J. Hsu, Patricia J. Simner, Yehudit Bergman, Amy J. Mathers, Pranita D. Tamma
Summary: In this article, we report a case of a 5-week-old infant with 8 days of S. maltophilia bacteremia while receiving TMP-SMX. Transitioning to cefiderocol monotherapy resulted in blood culture clearance within 24 hours, in the absence of any additional interventions. This is the first published case of the use of cefiderocol for a pediatric patient with an infection due to S. maltophilia. We review preclinical and clinical data that underscore why cefiderocol may be an effective treatment option for S. maltophilia infections.
OPEN FORUM INFECTIOUS DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Laurita Klimkaite, Ignas Ragaisis, Renatas Krasauskas, Modestas Ruzauskas, Edita Suziedeliene, Julija Armalyte
Summary: Soil, as a diverse habitat for microorganisms, contains both antibiotics and antibiotic resistance genes (ARGs). Bacteria naturally present in soil or water have innate ARGs to counteract the chemical compounds produced by competitors, making treatment difficult when these bacteria cause infections. By creating functional gene libraries using antibiotic-resistant bacteria from agricultural soils in Lithuania, we discovered novel variants of aminoglycoside and beta-lactam resistance genes. Our findings suggest that soil microorganisms possess a range of ARG variants that could potentially spread to clinical settings.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Genetics & Heredity
Quentin Menetrey, Pauline Sorlin, Estelle Jumas-Bilak, Raphael Chiron, Chloe Dupont, Helene Marchandin
Summary: In patients with cystic fibrosis, the lung microbiome experiences important selective pressures, leading to colonization by both common and emerging pathogens. Competitive interactions and evolutionary modifications among bacteria are major drivers of persistence in the CF lung, with emerging pathogens like Achromobacter xylosoxidans and Stenotrophomonas maltophilia becoming important members of the complex bacterial community in the CF lung.
Article
Public, Environmental & Occupational Health
Veronica Franca Diniz Rocha, Thiago Pereira Cavalcanti, Jailton Azevedo, Helena Ferreira Leal, Giulyana Evelyn Oliveira Silva, Allan Roberto Xavier Malheiros, Ledilce Almeida Ataide, Jose Admirco Lima Filho, Antonio Raimundo Pinto Almeida, Nadia de Andrade Khouri, Mitermayer Galvao Reis, Joice Neves Reis
Summary: An outbreak of bloodstream infections caused by Stenotrophomonas maltophilia and Burkholderia cepacia occurred among dialyzed patients at a large hemodialysis center in Brazil. After collecting water samples and identifying genetic patterns, it was found that the outbreak was due to microbial biofilm contamination of the piping system. Changing the entire plumbing system successfully ended the outbreak.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
(2021)
Article
Microbiology
Yue Li, Ailan Zhao, Qin Yu, Nan Yu, Yao Cui, Xiaohan Ma, Haican Liu, Ruibai Wang
Summary: Tuberculosis (TB) is a significant infectious disease in China and accurate diagnosis and treatment are vital for TB prevention and control. A study found that Stenotrophomonas maltophilia, a multidrug-resistant bacterium, was isolated from stored Mtb cultures and had a negative impact on TB diagnosis and treatment. S. maltophilia showed resistance to multiple anti-TB drugs and altered the drug sensitivity test results, requiring attention and further research.
MICROBIOLOGY SPECTRUM
(2023)
Article
Microbiology
Carina M. M. Hall, Nawarat Somprasong, Johannah P. P. Hagen, Roxanne Nottingham, Jason W. W. Sahl, Jessica R. R. Webb, Mark Mayo, Bart J. J. Currie, Yuwana Podin, David M. M. Wagner, Paul Keim, Herbert P. P. Schweizer
Summary: Cefiderocol is a siderophore cephalosporin designed for treating infections caused by beta-lactam and multidrug-resistant Gram-negative bacteria. Resistance in clinical B. pseudomallei isolates from Australia is caused by an uncharacterized mechanism. The PiuA outer membrane receptor plays a major role in cefiderocol nonsusceptibility in isolates from Malaysia.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Editorial Material
Microbiology
Daniel D. Rhoads
Summary: Stenotrophomonas maltophilia is inherently resistant to several antibiotics, making treatment challenging. Automated susceptibility testing for S. maltophilia is limited by the performance of commercial test systems, requiring practical implementation and risk mitigation strategies.
JOURNAL OF CLINICAL MICROBIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Rima Fanaei Pirlar, Jeroen Wagemans, Fabian Kunisch, Rob Lavigne, Andrej Trampuz, Mercedes Gonzalez Moreno
Summary: CUB19 is a novel bacteriophage that specifically targets the bacterial species Stenotrophomonas maltophilia. It exhibits stability over a wide range of temperatures and pH values and has potent antimicrobial and antibiofilm activity. The study also suggests that CUB19 is effective when co-administered with antibiotics, making it a promising targeted therapeutic agent against biofilm-associated Stenotrophomonas infections.
Article
Microbiology
Rebecca Horch, Diana Rasp, Annika Dietz, Ronald Ebbert, Joerg Steinmann, Ulrich E. Schaible, Uwe Mamat, Ralph Bertram
Summary: Stenotrophomonas maltophilia is an important nosocomial pathogen with intrinsic resistance to antibiotics. The implementation of tet regulation allows for the regulation of gene expression and provides a deeper understanding of its physiology and virulence.
MICROBIOLOGY SPECTRUM
(2023)
Article
Infectious Diseases
Filippo Medioli, Elena Casali, Agnese Viscido, Valentina Pistolesi, Mario Venditti, Alessandra Oliva
Summary: This article describes a challenging case of persistent Stenotrophomonas maltophilia bloodstream infection, which was successfully treated by adding the novel siderophore cephalosporin cefiderocol to a partially effective levofloxacin regimen. In addition, intra-lock therapy with trimethoprim/sulfamethoxazole was chosen to prevent infection recurrence due to the inability to achieve complete source control. The serum bactericidal assay was used to confirm the in vivo efficacy of the combination therapy.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)
Article
Biochemistry & Molecular Biology
Danuta Wojcieszynska, Judyta Klamka, Ariel Marchlewicz, Izabela Potocka, Joanna Zur-Pinska, Urszula Guzik
Summary: In this study, a plant sponge from Luffa cylindrica was used as a carrier for the immobilization of Stenotrophomonas maltophilia KB2 strain. The optimal conditions for immobilization were determined, and the immobilized strain showed potential for bioremediation processes.
Review
Microbiology
Joanna S. Brooke
Summary: Stenotrophomonas maltophilia is an opportunistic pathogen that can cause various infections and has intrinsic drug resistance. Research is ongoing to uncover new strategies to combat this pathogen, which possesses diverse virulence factors and adaptability to different environments.
CLINICAL MICROBIOLOGY REVIEWS
(2021)
Article
Infectious Diseases
Edeer Ivan Montoya-Hinojosa, Humberto Antonio Salazar-Sesatty, Cynthia A. A. Alvizo-Baez, Luis D. D. Terrazas-Armendariz, Itza E. E. Luna-Cruz, Juan M. M. Alcocer-Gonzalez, Licet Villarreal-Trevino, Samantha Flores-Trevino
Summary: The study aimed to investigate the effect of curcumin-chitosan nanocomplexes on biofilm-producing clinical isolates of non-fermenting Gram-negative bacilli. It was found that the combination of Cur-Chi-TPP-MNP with TMP-SXT could inhibit biofilm and eradicate established biofilms of clinical isolates of A. xylosoxidans, B. cepacia complex, and S. maltophilia species at lower concentrations.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2023)
Article
Infectious Diseases
Jovan Borjan, Kevin A. Meyer, Ryan K. Shields, Eric Wenzler
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2020)
Article
Critical Care Medicine
Manuela Haiduc, Sara Radparvar, Samuel L. Aitken, Jerry Altshuler
Summary: Transitioning norepinephrine to phenylephrine in septic shock patients with rapid atrial fibrillation may have a clinical effect on achieving rate control, but does not appear to significantly impact mortality or length of stay outcomes.
JOURNAL OF INTENSIVE CARE MEDICINE
(2021)
Letter
Microbiology
Nicolo L. Cabrera, Alexandre E. Malek, Samuel L. Aitken, Cesar A. Arias
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)
Editorial Material
Pharmacology & Pharmacy
Emily L. Heil, Samuel L. Aitken, David E. Nix, Richard Drew, Warren E. Rose, Susan L. Davis, Julie Ann Justo, Douglas N. Fish, Jason M. Pogue
Letter
Oncology
Michael Frei, Samuel L. Aitken, Nitin Jain, Philip Thompson, William Wierda, Dimitrios P. Kontoyiannis, Adam J. DiPippo
LEUKEMIA & LYMPHOMA
(2020)
Article
Hematology
Alexandre E. Malek, Cristina Gutierrez, Victor E. Mulanovich, Joshua Botdorf, Roy F. Chemaly, Shivan Shah, Brandi M. McCall, Judd T. Melancon, Kelly K. McConn, Jovan Borjan, Issam I. Raad, Jan A. Burger, Guillermo Garcia-Manero, Javier A. Adachi
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
(2020)
Article
Immunology
Eduardo A. Yepez Guevara, Samuel L. Aitken, Adilene Olvera, Lily Carlin, Kerri E. Fernandes, Micah M. Bhatti, Kevin W. Garey, Javier Adachi, Pablo C. Okhuysen
Summary: This study investigated Clostridioides difficile infection in cancer patients, finding that patients with EIA+ were older, more likely to fail therapy and experience recurrence, with the presence of ribotypes associated with poor outcomes increasing the risk of treatment failure.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Joseph Sassine, Fareed Khawaja, Terri Lynn Shigle, Victoria Handy, Farnaz Foolad, Samuel L. Aitken, Ying Jiang, Richard Champlin, Elizabeth Shpall, Katy Rezvani, Ella J. Ariza-Heredia, Roy F. Chemaly
Summary: Primary prophylaxis with letermovir in CMV-seropositive allogeneic HCT recipients is associated with significant reductions in refractory or resistant CMV infections, nonrelapse mortality at week 48, as well as CS-CMVi and CMV end-organ disease. This approach effectively prevents difficult-to-treat CMV infections and improves outcomes after allogeneic HCT.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Uri Greenbaum, Kimberly Klein, Fernando Martinez, Juhee Song, Peter F. Thall, Jeremy L. Ramdial, Cristina Knape, Fleur M. Aung, Jamie Scroggins, Adriana Knopfelmacher, Victor Mulanovich, Jovan Borjan, Javier Adachi, Mayoora Muthu, Cerena Leung, Mayrin Correa Medina, Richard Champlin, Amanda Olson, Amin Alousi, Katayoun Rezvani, Elizabeth J. Shpall
Summary: This study found that COVID-19 patients with higher levels of anti-HCoV-OC43 and anti-HCoV-HKU1 IgG antibodies had a higher survival rate, and these antibodies may target a common domain for SARS-CoV-2 and other coronaviruses, providing a promising therapeutic target for monoclonal antibody production.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Microbiology
Truc T. Tran, Sara Gomez Villegas, Samuel L. Aitken, Susan M. Butler-Wu, Alex Soriano, Brian J. Werth, Jose M. Munita
Summary: Long-acting lipoglycopeptides (LGPs) dalbavancin and oritavancin are semisynthetic antimicrobials with broad and potent activity against Gram-positive bacterial pathogens. This review discusses their use in the treatment of invasive infections, as well as the barriers preventing their optimal use and the ongoing clinical studies addressing these gaps.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Biology
Hiba Dagher, Anne-Marie Chaftari, Patricia Mulanovich, Ying Jiang, Ray Hachem, Alexandre E. Malek, Jovan Borjan, George M. Viola, Issam Raad
Summary: The study found that a PCT level of less than 0.25 ng/ml in cancer patients with COVID-19 is associated with a lower likelihood of bacterial co-infection and a shorter duration of antibiotic therapy. This suggests that PCT could be a useful biomarker to guide antibiotic treatment and enhance antimicrobial stewardship in cancer patients.
Article
Infectious Diseases
Elaine Liu, Andrea M. Prinzi, Jovan Borjan, Samuel L. Aitken, Patricia A. Bradford, William F. Wright
Summary: Antimicrobial resistance (AMR) is a global health crisis. Clinicians face challenges in treating patients with antimicrobial-resistant infections. A strong understanding of clinical microbiology, infectious diseases, and pharmacology can help clinicians navigate these cases. Important factors include laboratory testing, understanding pathogen resistance, recognizing resistance trends, identifying acquired AMR mechanisms, and considering these factors for an optimal pharmacological plan. This article outlines a novel framework for approaching clinical AMR, encourages education on AMR, and improves therapeutic decision-making in AMR-related illnesses.
JAC-ANTIMICROBIAL RESISTANCE
(2023)
Article
Immunology
Pranita D. Tamma, Samuel L. Aitken, Robert A. Bonomo, Amy J. Mathers, David van Duin, Cornelius J. Clancy
Summary: This guidance document provides recommendations for the treatment of antimicrobial-resistant infections caused by ESBL-E, CRE, and DTR-P. aeruginosa, with a focus on the United States. It discusses empiric treatment selection, duration of therapy, and other management considerations for both adults and children. The current version of the guidance is valid as of September 17, 2020, and will be updated periodically.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
William C. Shropshire, Samuel L. Aitken, Reed Pifer, Jiwoong Kim, Micah M. Bhatti, Xiqi Li, Awdhesh Kalia, Jessica Galloway-Pena, Pranoti Sahasrabhojane, Cesar A. Arias, David E. Greenberg, Blake M. Hanson, Samuel A. Shelburne
Summary: By analyzing genomic data and conducting serial passaging experiments on clinical ESBL-E isolates, this study revealed the IS26-mediated mechanisms of beta-lactamase gene amplification and outer membrane porin disruption driving the emergence of clinical non-CP-CRE. These amplifications were found to be stable in the absence of antimicrobial pressure, demonstrating the potential of long-read sequencing in identifying mobile genetic element mechanisms that contribute to antimicrobial resistance.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
